Hims & Hers flags possible halt to compounded weight-loss drug sales; shares slump
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
devdiscourse26m
Healthcare Dynamics: Challenges and Innovations Amid Global Shifts
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, MicroStrategy, PayPal, and More
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...
Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
There are dot-com echoes beyond tech. This Costco shareholder explains why returns will be paltry at best.
Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...
Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...